CL2011002814A1 - Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. - Google Patents
Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar.Info
- Publication number
- CL2011002814A1 CL2011002814A1 CL2011002814A CL2011002814A CL2011002814A1 CL 2011002814 A1 CL2011002814 A1 CL 2011002814A1 CL 2011002814 A CL2011002814 A CL 2011002814A CL 2011002814 A CL2011002814 A CL 2011002814A CL 2011002814 A1 CL2011002814 A1 CL 2011002814A1
- Authority
- CL
- Chile
- Prior art keywords
- dimethyl
- morpholin
- phenyl
- butyramide
- depressive
- Prior art date
Links
- OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 title abstract 3
- 230000003001 depressive effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 238000001228 spectrum Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900597 | 2009-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002814A1 true CL2011002814A1 (es) | 2012-04-13 |
Family
ID=42237259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002814A CL2011002814A1 (es) | 2009-05-11 | 2011-11-10 | Formas cristalinas de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; composicion farmaceutica; proceso de preparacion de n-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida; y uso en el tratamiento de esquizofrenia, trastornos convulsivos, depresivos y de espectro bipolar. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP2430008A2 (de) |
| JP (1) | JP2012526152A (de) |
| KR (1) | KR20120022934A (de) |
| CN (1) | CN102459208A (de) |
| AR (1) | AR076556A1 (de) |
| AU (1) | AU2010246724B2 (de) |
| BR (1) | BRPI1013930A2 (de) |
| CA (1) | CA2761383A1 (de) |
| CL (1) | CL2011002814A1 (de) |
| CO (1) | CO6460741A2 (de) |
| CR (1) | CR20110590A (de) |
| DO (1) | DOP2011000351A (de) |
| EA (1) | EA201171381A1 (de) |
| GE (1) | GEP20146006B (de) |
| IL (1) | IL216148A0 (de) |
| MA (1) | MA33351B1 (de) |
| MX (1) | MX2011011885A (de) |
| NZ (1) | NZ596738A (de) |
| SG (1) | SG175968A1 (de) |
| TN (1) | TN2011000557A1 (de) |
| TW (1) | TW201041857A (de) |
| WO (1) | WO2010130260A2 (de) |
| ZA (1) | ZA201108112B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119490430A (zh) | 2019-08-02 | 2025-02-21 | H.隆德贝克有限公司 | 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI349666B (en) * | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| BRPI0716715B1 (pt) * | 2006-08-23 | 2021-07-06 | Xenon Pharmaceuticals, Inc | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula |
| EP2185149A1 (de) * | 2007-08-01 | 2010-05-19 | H. Lundbeck A/S | Verwendung von kncq-kaliumkanal-öffnern zur verringerung von symptomen oder zur behandlung von erkrankungen oder störungen mit unterbrechung des dopaminergen systems |
-
2010
- 2010-05-06 TW TW099114459A patent/TW201041857A/zh unknown
- 2010-05-10 AR ARP100101588A patent/AR076556A1/es unknown
- 2010-05-11 KR KR1020117026958A patent/KR20120022934A/ko not_active Withdrawn
- 2010-05-11 JP JP2012510116A patent/JP2012526152A/ja active Pending
- 2010-05-11 MX MX2011011885A patent/MX2011011885A/es not_active Application Discontinuation
- 2010-05-11 BR BRPI1013930A patent/BRPI1013930A2/pt not_active IP Right Cessation
- 2010-05-11 WO PCT/DK2010/050101 patent/WO2010130260A2/en not_active Ceased
- 2010-05-11 CA CA2761383A patent/CA2761383A1/en not_active Abandoned
- 2010-05-11 SG SG2011082492A patent/SG175968A1/en unknown
- 2010-05-11 GE GEAP201012498A patent/GEP20146006B/en unknown
- 2010-05-11 CN CN2010800321765A patent/CN102459208A/zh active Pending
- 2010-05-11 AU AU2010246724A patent/AU2010246724B2/en not_active Ceased
- 2010-05-11 EA EA201171381A patent/EA201171381A1/ru unknown
- 2010-05-11 EP EP10719726A patent/EP2430008A2/de not_active Withdrawn
- 2010-05-11 NZ NZ596738A patent/NZ596738A/xx not_active IP Right Cessation
- 2010-05-11 MA MA34435A patent/MA33351B1/fr unknown
-
2011
- 2011-11-03 IL IL216148A patent/IL216148A0/en unknown
- 2011-11-04 TN TNP2011000557A patent/TN2011000557A1/en unknown
- 2011-11-04 ZA ZA2011/08112A patent/ZA201108112B/en unknown
- 2011-11-10 CL CL2011002814A patent/CL2011002814A1/es unknown
- 2011-11-11 CR CR20110590A patent/CR20110590A/es unknown
- 2011-11-11 DO DO2011000351A patent/DOP2011000351A/es unknown
- 2011-11-11 CO CO11153611A patent/CO6460741A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG175968A1 (en) | 2011-12-29 |
| IL216148A0 (en) | 2012-01-31 |
| MA33351B1 (fr) | 2012-06-01 |
| TW201041857A (en) | 2010-12-01 |
| BRPI1013930A2 (pt) | 2019-09-24 |
| CA2761383A1 (en) | 2010-11-18 |
| NZ596738A (en) | 2013-04-26 |
| CN102459208A (zh) | 2012-05-16 |
| EP2430008A2 (de) | 2012-03-21 |
| WO2010130260A2 (en) | 2010-11-18 |
| JP2012526152A (ja) | 2012-10-25 |
| MX2011011885A (es) | 2011-12-06 |
| TN2011000557A1 (en) | 2013-05-24 |
| CO6460741A2 (es) | 2012-06-15 |
| AR076556A1 (es) | 2011-06-22 |
| KR20120022934A (ko) | 2012-03-12 |
| WO2010130260A3 (en) | 2011-06-16 |
| GEP20146006B (en) | 2014-01-10 |
| AU2010246724A1 (en) | 2011-12-08 |
| EA201171381A1 (ru) | 2012-05-30 |
| CR20110590A (es) | 2012-02-22 |
| WO2010130260A9 (en) | 2012-10-18 |
| ZA201108112B (en) | 2013-01-30 |
| DOP2011000351A (es) | 2012-01-31 |
| AU2010246724B2 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2009000200A1 (es) | Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune. | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| CL2008001818A1 (es) | Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras. | |
| CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
| BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil |